Ignite Creation Date:
2025-12-24 @ 2:50 PM
Ignite Modification Date:
2026-02-27 @ 8:48 AM
Study NCT ID:
NCT05396859
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-17
First Post:
2022-04-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
Sponsor:
OHSU Knight Cancer Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
STUDY00023205
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None